Tiphaine Pierson has received research support from the Canadian Medication Appropriateness and Deprescribing Network, a health organization that receives funding from Health Canada, Accelerating Clinical Trials Canada, and the Canadian Institute of Health Research. Verna Arcand received travel support and speaker honoraria from the Canadian Medication Appropriateness and Deprescribing Network to attend the National Meeting. Barbara Farrell receives annual honoraria from the US Deprescribing Research Network for her participation as a member of their Scientific Advisory Board, as well as travel expenses from the latter and from the Canadian Medication Appropriateness and Deprescribing Network to attend annual meetings. Camille L. Gagnon is assistant director of the Canadian Medication Appropriateness and Deprescribing Network, a health organization that receives funding from Health Canada, the Canadian Institutes of Health Research, and Accelerated Clinical Trials Canada. Larry Leung received travel support from the Canadian Medication Appropriateness and Deprescribing Network to attend the National Meeting. He serves as a volunteer member of the board of directors for Indigicare Medicines Ltd. Lisa M. McCarthy received travel support from the Canadian Medication Appropriateness and Deprescribing Network to attend the National Meeting, and receives funding from Health Canada, Canadian Institutes of Health Research, Ontario Centres for Learning, Research & Innovation in Long-Term Care, and the University of Toronto. Andrea L. Murphy is a co-lead for Sleepwell and has received funding from the Drug Evaluation Alliance of Nova Scotia, and with the Canadian Medication Appropriateness and Deprescribing Network received funding from the Canadian Drug Agency Transition Office. Nav Persaud received travel support from the Canadian Medication Appropriateness and Deprescribing Network to attend the National Meeting, and receives research funding from the Canadian Institutes of Health Research, Ontario SPOR Support Unit, and St Michael’s Hospital Foundation. Lalitha Raman-Wilms received travel support from the Canadian Medication Appropriateness and Deprescribing Network to attend the National Meeting. James L. Silvius is the executive director of the Canadian Medication Appropriateness and Deprescribing Network, a health organization that receives funding from Health Canada, the Canadian Institutes of Health Research, and Accelerated Clinical Trials Canada. James L. Silvius is also the Provincial Medical Director for Seniors Health and Senior Medical Director at Alberta Health Services, and both the chair of the Canadian Drug Expert Committee and a member of the Formulary Management Expert Committee at Canada’s Drug and Health Technology Agency. Michael A. Steinman received travel support from the Canadian Medication Appropriateness and Deprescribing Network to attend the National Meeting, and receives royalties from UpToDate, as well as honoraria from the American Geriatrics Society. Cara Tannenbaum receives financial compensation through a university interchange in her role as departmental science advisor to Health Canada since 2020. Cara Tannenbaum co-founded CaDeN and was its co-director from 2015–2019. Wade Thompson received travel support from the Canadian Medication Appropriateness and Deprescribing Network to attend the National Meeting, received research funding from Health Canada, the Canadian Institutes of Health Research, Michael Smith Health Research BC, and National Institute on Aging (USA), and received an honorarium from Pharmacy Practice Plus magazine for an article on deprescribing. Johanna Trimble received travel support from the Canadian Medication Appropriateness and Deprescribing Network to attend the National Meeting. Cheryl A. Sadowski received travel support from the Canadian Medication Appropriateness and Deprescribing Network to attend the National Meeting, and received research funding from the Indigenous Wellness Core, the Social Sciences and Humanities Research Council, and the Indigenous Primary Health Care & Policy Research Network. Emily G. McDonald is the scientific director of the Canadian Medication Appropriateness and Deprescribing Network, a health organization that receives funding from Health Canada, the Canadian Institute of Health Research, and Accelerating Clinical Trials Canada. Emily G. McDonald has received funding from the Canadian Institute of Health Research and the Centre for Aging and Brain Health Innovation for her ongoing research evaluating the impact of MedSafer on prescribing practices. Emily G. McDonald is the CEO of MedSafer, the copyright for which is jointly held with McGill University and one other.